Compare Amphastar Pharmaceuticals Inc (AMPH) vs UnitedHealth Group Inc (UNH) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

UnitedHealth Group (UNH) trades at $424.62, down 1.64% on the day, slightly above the analyst consensus price target of $423.18. The stock shows bullish technical signals with strong moving average support and recent earnings beats in three consecutive quarters. Revenue has grown consistently from $322.1B in 2022 to $447.6B in 2025, though net income margin has compressed from 6.24% to 2.69% over the same period. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns through dividends and buybacks.

Outlook remains positive with 82.7% analyst buy ratings and strong institutional support, driven by aging demographics and healthcare innovation. Key risks include regulatory scrutiny (Massachusetts Medicaid lawsuit filed May 29, 2026), margin pressure from rising costs, and increasing debt levels. The current P/E of 31.97 appears elevated relative to historical norms, suggesting valuation sensitivity to earnings growth.